Long-term overall survival in a patient with non-small cell lung cancer with KRAS mutation

The prognosis of patients with metastatic non-small cell lung cancer depends not only on the general condition and stage of the disease but also on the treatment method. Management of lung cancer in stage 4, usually requires a multidisciplinary approach. Frequently in the treatment process, we combine local and systemic treatment. By detecting new therapeutic targets, we can incorporate new elements of therapy. In the described case, the treatment sequence: chemotherapy, immunotherapy, targeted treatment combined with symptomatic local treatment resulted in prolonged survival time and maintaining a good quality of life. The new molecule sotorasib is a drug targeting the G12C mutation in the Kirsten rat sarcoma virus (KRAS) gene approved by the FDA and EMA.